Dr. Mundy appointed as SBC Communications chair, director of IDD
Dr. Gregory R. Mundy, professor and chief of the division of endocrinology and metabolism in the department of medicine, has been named as the SBC Communications chair and director of the CTRC's Institute for Drug Development (IDD). Dr. Mundy has been with the Health Science Center since 1980. He also is the Joseph C. and Irene Heyser Professor of Bone and Mineral Metabolism.
A native of Australia, Dr. Mundy is board certified in internal medicine, endocrinology and metabolism and serves on a number of National Institutes of Health study groups, editorial boards and company advisory panels.
As the SBC Communications chair, Dr. Mundy will direct the activities of a staff of 139 with a budget of $13.1 million. The IDD is a private, non-profit, medical research organization whose mission is to develop, through the integration of research programs of excellence in the basic, translational and clinical sciences, new treatments for patients with cancer.
"Dr. Mundy is one of the Health Science Center's research stars," said Dr. Francisco G. Cigarroa, Health Science Center president. "With Dr. Mundy in this new and important role, I am confident the university will have even closer collaboration with the CTRC."
Dr. Charles A. Coltman Jr., professor in the department of medicine and president and CEO of the CTRC, said he looks forward to working with Dr. Mundy in this new role.
"Dr. Greg Mundy brings an exciting new perspective to the IDD," said Dr. Coltman. "He is an internationally known bone and cancer metastasis researcher who will lead the institute through a period of vigorous growth and facilities consolidation, and on to its next level of excellence."